#SNTI hashtag - Bluesky

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update Senti Biosciences (Nasdaq: SNTI) reported fourth-quarter and full-year 2025 results and a corporate update on March 27, 2026. Key highlights: RMAT designation for SENTI-202 in relapsed/refractory AML, updated positive preliminary Phase 1 data for SENTI-202, and continued Gene Circuit platform progress.Financials: $16.4M cash at Dec 31, 2025; Q4 R&D $7.8M; FY2025 R&D $37.6M; Q4 G&A $5.8M; FY2025 G&A $26.2M; Q4 net loss $14.5M ($0.53/share); FY net loss $61.4M ($2.73/share) including a $5.1M impairment and $5.7M stock‑based comp.

1 week ago

#SNTI Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/SNTI/senti-bio-repo...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

3 months ago

Senti Bio Receives FDA RMAT Designation for SENTI-202 in Relapsed/Refractory AML Senti Biosciences, Inc. (Nasdaq: SNTI) announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designatio

Senti Bio (NASDAQ: #SNTI) received FDA RMAT designation for SENTI-202 after Phase 1 data showed strong response rates and durable remissions in relapsed/refractory AML. The off-the-shelf CAR-NK therapy now moves onto an expedited development path with FDA support.
prismmarketview.com/senti-bio-re...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Most Searched, Tuesday December 9, 2025 – Crystal Equity Research

Most searched small-cap stocks, Tue Dec 9th - #RXRX #EXK #NVTS #RR #TROX #XCUR #IRBT #VOR #SNTI #SBET #UUUU #SEI #SANA #PLUG #ONDS #GCT #CLSK #BITF #BBAI - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Stock Master

@stockmaster70.bsky.social

3 months ago

📢 Stocks Trending NOW: #NVDA #XCUR #VOR #WVE #PSKY #ATMC #CVS #SNTI #AZO #CPB

0 0 0 0

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 Senti Biosciences (NASDAQ:SNTI), a clinical-stage biotech company, has reported its Q2 2025 financial results and provided key updates on its SENTI-202 program for Acute Myeloid Leukemia (AML). The company has completed the dose-finding phase and confirmed the recommended Phase 2 dose (RP2D) in its ongoing Phase 1 clinical trial. SENTI-202 received FDA Orphan Drug Designation for AML treatment.Financial highlights include cash position of $21.6M as of June 30, 2025 (down from $48.3M in December 2024), R&D expenses of $10.0M (up $0.8M YoY), and G&A expenses of $6.8M (up $2.6M YoY). The company reported a net loss of $14.7M ($0.56 per share) for Q2 2025. Additionally, Senti Bio secured a $1.0M grant from CIRM for SENTI-202's clinical development.

7 months ago

#SNTI Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

www.stocktitan.net/news/SNTI/senti-bio-repo...

0 0 0 0

Exclusive: Senti Bio CEO Reveals Personal Journey and Strategic Vision for Gene Circuit Platform Watch Senti Bio CEO Dr. Timothy Lu discuss his journey and strategic vision for the company's innovative Gene Circuit platform. Access exclusive insights now.

8 months ago

#SNTI Senti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

www.stocktitan.net/news/SNTI/senti-bioscien...

0 0 0 0

Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company, announced that its Chief Medical Officer, Dr. Kanya Rajangam, will deliver a presentation at the BioScience Forum on July 23, 2025 in San Carlos, CA.The presentation, titled "Using Logic Gated CARs to Drive Cancer Treatment," will showcase Senti Bio's innovative logic-gated CAR-NK cell therapy technology, which is designed to target leukemic cells while preserving healthy bone marrow. The BioScience Forum serves the Bay Area biotechnology community by featuring discussions on cutting-edge discoveries in therapeutic areas including oncology and infectious diseases.

8 months ago

#SNTI Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

www.stocktitan.net/news/SNTI/senti-bio-s-ch...

0 0 0 0

Senti Bio Participates in Nasdaq Amplify Spotlight Series Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company, participated in Nasdaq's Amplify Spotlight Series. CEO and Co-Founder Timothy Lu presented a corporate overview highlighting the company's proprietary Gene Circuit platform for developing next-generation cell and gene therapies.The company's lead program, SENTI-202, is a first-in-class off-the-shelf CAR NK cell therapy targeting CD33 and/or FLT3-expressing hematologic malignancies, including AML and myelodysplastic syndrome (MDS). The therapy is currently in Phase 1 clinical trials and has shown positive preliminary data. Notably, SENTI-202 has received Orphan Drug Designation from the FDA for treating relapsed/refractory hematologic malignancies including AML.

9 months ago

#SNTI Senti Bio Participates in Nasdaq Amplify Spotlight Series

www.stocktitan.net/news/SNTI/senti-bio-part...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Wed Jun 18th - #SNTI #INV #IMDX #EKSO #DXLG #BNTC #ACB #DDD #BPT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Pomerantz Law Firm Investigates Potential Fraud Claims Against Senti Biosciences, Inc. Pomerantz Law Firm is conducting an investigation into potential claims of securities fraud against Senti Biosciences, Inc. after a significant stock drop.

@marketwirenews.com

9 months ago

JUST IN: ( NASDAQ: #SNTI ) Senti Biosciences Announces New Employment Inducement Grants

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Pomerantz Law Firm Investigates Potential Fraud Claims Against Senti Biosciences, Inc. #USA #New_York #Pomerantz_LLP #Senti_Biosciences #SNTI

0 0 0 0

Senti Bio Cancer Therapy Achieves 71% Response Rate in AML Patients, Secures Additional $1M CIRM Grant Latest Phase 1 data reveals promising 71% response rate for novel CAR-NK cell therapy in AML patients. Additional $1M grant supports advancing treatment. See full results.

10 months ago

#SNTI Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

www.stocktitan.net/news/SNTI/senti-bio-rece...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Investors of Senti Biosciences, Inc. May Join Fraud Investigation Led by Schall Law Firm The Schall Law Firm is initiating an investigation for Senti Biosciences, Inc. investors regarding potential securities law violations linked to the company's drug trial cancellation.

Investors of Senti Biosciences, Inc. May Join Fraud Investigation Led by Schall Law Firm #United_States #Los_Angeles #Schall_Law_Firm #Senti_Biosciences #SNTI

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Legal Investigation Launched for Investors of Senti Biosciences, Inc. Amid Stock Decline Pomerantz Law Firm is investigating potential securities fraud involving Senti Biosciences, prompting investors to take action. Read more about the implications.

Legal Investigation Launched for Investors of Senti Biosciences, Inc. Amid Stock Decline #USA #New_York #Pomerantz_LLP #Senti_Biosciences #SNTI

0 0 0 0

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 Senti Biosciences (SNTI) has released a mechanism of action video for SENTI-202, their first-in-class off-the-shelf CAR NK cell therapy. The therapy targets CD33 and/or FLT3-expressing hematologic malignancies like AML and MDS. SENTI-202 features three key components: an OR Logic Gate targeting leukemia cells, a NOT Logic Gate protecting healthy cells, and calibrated IL-15 release enhancing immune response. The ongoing Phase 1 trial shows promising results with no dose-limiting toxicities. At the preliminary recommended Phase 2 dose, 2 of 3 patients achieved complete remission. Overall, 5 of 7 evaluable patients showed response, with 4 achieving complete remission. All complete remission patients remain in remission with 4+ to 8+ months of follow-up.

10 months ago

#SNTI Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202

www.stocktitan.net/news/SNTI/senti-bio-rele...

1 0 0 0

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development Senti Biosciences (NASDAQ: SNTI) reported positive Phase 1 clinical trial results for SENTI-202, its lead program for treating relapsed/refractory hematologic malignancies including AML. Key highlights include: The trial showed SENTI-202 was well-tolerated with 4 out of 7 patients achieving composite Complete Remission (cCR). All cCR patients were MRD negative and maintained responses ranging from 4+ to 8+ months. The preliminary recommended Phase 2 dose was identified at 1.5 x 109 CAR NK cells. Financial results for Q1 2025 showed cash and cash equivalents of $33.8 million. R&D expenses increased to $9.3 million from $8.8 million year-over-year, while G&A expenses decreased to $7.1 million from $7.5 million. The company reported a net loss of $14.1 million ($1.41 per share).

10 months ago

#SNTI Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development

www.stocktitan.net/news/SNTI/senti-bio-repo...

0 0 0 0

Breakthrough Leukemia Treatment: Senti Bio's CAR-NK Therapy Shows Promising Phase 1 Results at AACR 2025 New clinical data reveals effectiveness of SENTI-202 CAR-NK cell therapy in treating resistant AML. CMO discusses breakthrough treatment approach. See trial results.

11 months ago

#SNTI Senti Bio Releases Virtual Investor “What This Means” Segment

www.stocktitan.net/news/SNTI/senti-bio-rele...

0 0 0 0

Top Leukemia Experts Reveal Latest AML Treatment Breakthroughs: Senti Bio's SENTI-202 Program in Focus Sarah Cannon's Leukemia Director joins Senti Bio CMO to discuss groundbreaking AML treatment advances. Access exclusive insights on SENTI-202 program. Watch Now.

11 months ago

#SNTI Senti Bio Participates in a Virtual Investor KOL Connect Segment

www.stocktitan.net/news/SNTI/senti-bio-part...

0 0 0 0

Clinical-Stage Biotech Senti Bio Launches New Investor Hub on Webull Clinical-stage biotech Senti Bio expands shareholder engagement via Webull CCS while advancing SENTI-202 therapy for acute myeloid leukemia. See latest updates.

11 months ago

#SNTI Senti Bio Joins Webull Corporate Connect Service Platform

www.stocktitan.net/news/SNTI/senti-bio-join...

0 0 0 0

Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights Senti Biosciences (NASDAQ: SNTI) has reported its Q4 and full-year 2024 financial results, highlighting significant clinical progress and financial developments. The company's lead product SENTI-202 showed promising initial Phase 1 results, with 2 out of 3 relapsed/refractory AML patients achieving MRD negative complete remission at the lowest dose level, maintaining remission as of March 2025.The company substantially strengthened its financial position through a $47.6 million PIPE financing led by Celadon Partners, with participation from notable investors. The net proceeds of $45.1 million are expected to extend the company's runway into 2026. Additionally, Senti Bio received $1.5 million from CIRM, bringing total grant funding to $6.4 million.Financial results show cash and cash equivalents of $48.3 million as of December 31, 2024. Q4 R&D expenses decreased to $7.8 million from $9.1 million year-over-year, while G&A expenses reduced to $8.4 million from $9.3 million. The company reported a Q4 net loss of $0.6 million ($0.67 per share) and a full-year 2024 net loss of $52.8 million ($12.03 per share).

1 year ago

#SNTI Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights

www.stocktitan.net/news/SNTI/senti-bio-anno...

0 0 0 0

@sentibio.bsky.social

1 year ago

Companies To Watch: Senti Bio <p>Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells.</p>

Our CEO, Tim Lu, MD, PhD, spoke with @benmcomer.bsky.social at Life Science Leader to share insights on how we plan to improve #celltherapies in oncology utilizing our logic gating technology to pinpoint diseased cells and spare healthy ones. Thanks so much for including us! #SNTI bit.ly/3Et3zM4

0 0 0 0

Senti Bio Secures $11.5M Boost: Extends Cash Runway to 2026 with New Funding Round Senti Biosciences raises $10M from Celadon Partners and secures $1.5M CIRM grant, extending total PIPE financing to $47.6M. Funding bolsters SENTI-202 program development.

1 year ago

#SNTI Senti Bio Announces Additional $11.5 Million of Financing

www.stocktitan.net/news/SNTI/senti-bio-anno...

0 0 0 0

Senti Bio Launches Groundbreaking CAR-NK Cell Therapy Trial for Liver Cancer in China Senti Biosciences initiates clinical trial of SN301A, an innovative CAR-NK cell therapy, for hepatocellular carcinoma patients in China through strategic Celest partnership.

1 year ago

#SNTI Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

www.stocktitan.net/news/SNTI/senti-bio-anno...

0 0 0 0

@marketwirenews.com

1 year ago

JUST IN: ( NASDAQ: #SNTI ) December is Already Lit

#StockMarket #News

0 0 0 0

@marketwirenews.com

1 year ago

News; ( NASDAQ: #SNTI ) Senti Biosciences Reports Oversubscribed $37.6 M PIPE Financing

#StockMarket #News

0 0 0 0